WO2002020500A2 - Materials and methods to potentiate cancer treatment - Google Patents

Materials and methods to potentiate cancer treatment Download PDF

Info

Publication number
WO2002020500A2
WO2002020500A2 PCT/US2001/026709 US0126709W WO0220500A2 WO 2002020500 A2 WO2002020500 A2 WO 2002020500A2 US 0126709 W US0126709 W US 0126709W WO 0220500 A2 WO0220500 A2 WO 0220500A2
Authority
WO
WIPO (PCT)
Prior art keywords
moφholin
phenyl
hydroxy
group
dna
Prior art date
Application number
PCT/US2001/026709
Other languages
English (en)
French (fr)
Other versions
WO2002020500A3 (en
Inventor
James Halbrook
Edward Kesicki
Laurence E. Burgess
Stephen T. Schlachter
Charles T. Eary
Justin G. Schiro
Hongmei Huang
Michael Evans
Yongxin Han
Original Assignee
Icos Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corporation filed Critical Icos Corporation
Priority to EP01968164A priority Critical patent/EP1351946A2/en
Priority to AU2001288432A priority patent/AU2001288432A1/en
Publication of WO2002020500A2 publication Critical patent/WO2002020500A2/en
Publication of WO2002020500A3 publication Critical patent/WO2002020500A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/30—Nitrogen atoms non-acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6578—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and sulfur atoms with or without oxygen atoms, as ring hetero atoms
    • C07F9/65785—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and sulfur atoms with or without oxygen atoms, as ring hetero atoms the ring phosphorus atom and, at least, one ring sulfur atom being part of a thiophosphonic acid derivative
PCT/US2001/026709 2000-09-01 2001-08-28 Materials and methods to potentiate cancer treatment WO2002020500A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01968164A EP1351946A2 (en) 2000-09-01 2001-08-28 Materials and methods to potentiate cancer treatment
AU2001288432A AU2001288432A1 (en) 2000-09-01 2001-08-28 Materials and methods to potentiate cancer treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22989900P 2000-09-01 2000-09-01
US60/229,899 2000-09-01

Publications (2)

Publication Number Publication Date
WO2002020500A2 true WO2002020500A2 (en) 2002-03-14
WO2002020500A3 WO2002020500A3 (en) 2003-07-31

Family

ID=22863116

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/026709 WO2002020500A2 (en) 2000-09-01 2001-08-28 Materials and methods to potentiate cancer treatment

Country Status (4)

Country Link
US (2) US7179912B2 (US07179912-20070220-C00074.png)
EP (1) EP1351946A2 (US07179912-20070220-C00074.png)
AU (1) AU2001288432A1 (US07179912-20070220-C00074.png)
WO (1) WO2002020500A2 (US07179912-20070220-C00074.png)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110418A2 (en) * 2003-06-10 2004-12-23 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
WO2004085418A3 (en) * 2003-03-24 2005-01-27 Icos Corp Xanthones, thioxanthones and acridinones as dna-pk inhibitors
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
US7105518B2 (en) 2001-08-14 2006-09-12 Cancer Research Technology Limited Thiopyrane-4-ones as DNA protein kinase inhibitors
WO2006117669A1 (en) * 2005-05-03 2006-11-09 Pfizer Inc. Amide resorcinol compounds
EP1729770A1 (en) * 2004-03-15 2006-12-13 Sunesis Pharmaceuticals, Inc. Sns-595 and methods of using the same
US7179912B2 (en) 2000-09-01 2007-02-20 Icos Corporation Materials and methods to potentiate cancer treatment
US7226918B2 (en) 2001-08-14 2007-06-05 Cancer Research Technology Limited DNA-PK inhibitors
US7271195B2 (en) 2003-06-10 2007-09-18 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
US7402607B2 (en) 2004-09-20 2008-07-22 Kudos Pharmaceuticals Limited DNA-PK inhibitors
US7429660B2 (en) 2003-08-13 2008-09-30 Kudos Pharmaceuticals Limited ATM inhibitors
US7632838B2 (en) 2006-02-07 2009-12-15 Wyeth 11-beta HSD1 inhibitors
US7642254B2 (en) 2005-02-09 2010-01-05 Kudos Pharmaceuticals Limited ATM inhibitors
US7687499B2 (en) 2005-09-16 2010-03-30 Janssen Pharmaceutica Nv Cyclopropyl amines as modulators of the histamine H3 receptor
US7696203B2 (en) 2005-04-15 2010-04-13 Kudos Pharmaceuticals Limited DNA-PK inhibitors
US7834178B2 (en) 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
US7893257B2 (en) 2006-12-14 2011-02-22 Janssen Pharmaceutica Nv Process for the preparation of piperazinyl and diazepanyl benzamide derivatives
WO2011109387A1 (en) * 2010-03-01 2011-09-09 Intraop Medical Corporation Radiotherapy combined with hypoxic cell sensitizers
WO2011113512A1 (de) * 2010-03-16 2011-09-22 Merck Patent Gmbh Morpholinylchinazoline
WO2011123890A1 (en) 2010-04-06 2011-10-13 Peter Maccallum Cancer Institute Radioprotector compounds and methods
AU2006233256B2 (en) * 2006-10-30 2012-01-19 Armaron Bio Pty Ltd Improved flavonols
US8124773B2 (en) 2006-06-12 2012-02-28 Sunesis Pharmaceuticals, Inc. 1,8-naphthyridine compounds for the treatment of cancer
US8153793B2 (en) 2005-09-27 2012-04-10 Shionogi & Co., Ltd. Sulfonamide derivative having PGD2 receptor antagonistic activity
US8269197B2 (en) 2009-07-22 2012-09-18 Intraop Medical Corporation Method and system for electron beam applications
JP2013504544A (ja) * 2009-09-11 2013-02-07 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
WO2013072015A1 (de) * 2011-11-18 2013-05-23 Merck Patent Gmbh Morpholinylbenzotriazine zur anwendung in der krebstherapie
US8518872B2 (en) 2007-10-22 2013-08-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
US8580814B2 (en) 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
WO2014159690A1 (en) * 2013-03-12 2014-10-02 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
WO2015058031A1 (en) * 2013-10-17 2015-04-23 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
CN104640852A (zh) * 2012-04-24 2015-05-20 沃泰克斯药物股份有限公司 Dna-pk抑制剂
US9133178B2 (en) 2010-10-27 2015-09-15 Proximagen Limited Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer'S disease
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
EA024384B1 (ru) * 2013-06-27 2016-09-30 Институт Нефтехимических Процессов Им. Академика Ю. Мамедалиева, Нан Азербайджана Применение комплексной соли 2-морфолилметил-5-метилфенола в качестве пестицида против оидиума в плодах и листьях винограда
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
US10039761B2 (en) 2013-10-17 2018-08-07 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
CN111978139A (zh) * 2020-09-04 2020-11-24 许昌学院 一种水相中光催化一锅法合成苯酚或其衍生物的方法
US11072618B2 (en) 2016-12-09 2021-07-27 Denali Therapeutics Inc. Compounds, compositions and methods
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
US11129828B2 (en) 2011-08-22 2021-09-28 Takeda Pharmaceutical Company Limited Pyridazinone compounds and their use as DAAO inhibitors
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
US11413255B2 (en) * 2015-06-29 2022-08-16 Montefiore Medical Center Multifunctional cytoprotectant for treatment of pathogenic processes mediated by oxidative stress and toxic electrophiles
CN114933528A (zh) * 2022-05-30 2022-08-23 湖南大学 一种制备芳酰氧基烷基碘化物及其转化应用方法的新方法
US11603523B2 (en) 2019-01-18 2023-03-14 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
US11980633B2 (en) 2021-07-29 2024-05-14 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2302106T3 (es) * 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
US20030028018A1 (en) * 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
US6875165B2 (en) * 2001-02-22 2005-04-05 Retinalabs, Inc. Method of radiation delivery to the eye
WO2002082988A2 (en) * 2001-04-16 2002-10-24 The Johns Hopkins University Method for imaging and spectroscopy of tumors and determination of the efficacy of anti-tumor drug therapies
AU2003288899B2 (en) * 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US20060058313A1 (en) * 2002-11-12 2006-03-16 Hohneker John A Treatment of mesothelioma
EP1565187A4 (en) * 2002-11-13 2010-02-17 Novartis Vaccines & Diagnostic CANCER TREATMENT METHODS AND RELATED METHODS
US7273445B2 (en) * 2003-04-30 2007-09-25 Board Of Trustees Of The University Of Illinois Intraocular brachytherapy device and method
JP4724665B2 (ja) * 2003-11-07 2011-07-13 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キノリノン化合物を合成する方法
WO2005079915A1 (en) * 2004-02-12 2005-09-01 Neo Vista, Inc. Methods and apparatus for intraocular brachytherapy
US7803103B2 (en) * 2005-02-11 2010-09-28 Neovista Inc. Methods and apparatus for intraocular brachytherapy
CA2556872C (en) * 2004-02-20 2015-05-12 Chiron Corporation Modulation of inflammatory and metastatic processes
ES2374570T3 (es) * 2005-01-27 2012-02-17 Novartis Vaccines And Diagnostics, Inc. Tratamiento de tumores metastalizados.
US20060234959A1 (en) * 2005-04-14 2006-10-19 Advanced Photodynamic Technologies, Inc. Photodynamic therapy utilizing multiple duty cycle light modulation
MX2007014206A (es) 2005-05-13 2008-02-07 Novartis Ag Metodos para tratar cancer resistente a los farmacos.
KR101324863B1 (ko) * 2005-05-17 2013-11-01 노파르티스 아게 헤테로고리 화합물의 합성 방법
KR101368519B1 (ko) 2005-05-23 2014-02-27 노파르티스 아게 결정형 및 기타 형태의 4-아미노-5-플루오로-3-［6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일］-1ｈ-퀴놀린-2-온 락트산염
US8093246B2 (en) * 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
CA2679882C (en) 2007-03-08 2015-12-29 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
EP2170338A2 (en) * 2007-07-06 2010-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna-pkcs modulates energy regulation and brain function
TW200924762A (en) 2007-11-02 2009-06-16 Vertex Pharma Kinase inhibitors
EP3108933B1 (en) 2008-01-07 2019-09-18 Salutaris Medical Devices, Inc. Devices for minimally-invasive extraocular delivery of radiation to the posterior portion of the eye
US8608632B1 (en) 2009-07-03 2013-12-17 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive extraocular delivery of radiation and/or pharmaceutics to the posterior portion of the eye
US8353812B2 (en) 2008-06-04 2013-01-15 Neovista, Inc. Handheld radiation delivery system
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
US7825392B2 (en) * 2008-10-08 2010-11-02 Rodney Wayne Prosser Cleaning process for radiopharmaceutical reusable pigs
EP2349279A4 (en) 2008-10-28 2013-12-25 Univ Leland Stanford Junior ALDEHYDE DEHYDROGENASE MODULATORS AND METHOD OF USE THEREOF
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
US8642007B2 (en) 2010-09-20 2014-02-04 Yanping Kong Method and compound for treatment of cancer using phosphorous-32 labeled DNA
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
CN105884827B (zh) * 2015-02-13 2018-03-13 山东轩竹医药科技有限公司 嘧啶酰胺衍生物及其盐

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1355173A (fr) * 1962-04-12 1964-03-13 Science Union & Cie Préparation de nouveaux dérivés de l'acide salicylique
FR8298M (US07179912-20070220-C00074.png) * 1967-07-20 1970-11-16
DE2922488A1 (de) * 1979-06-01 1980-12-11 Thiemann Chem Pharm Fab 2-hydroxy-4-methyl-benzolverbindungen, verfahren zu ihrer herstellung und ihre verwendung
EP0078241A2 (de) * 1981-10-28 1983-05-04 Ciba-Geigy Ag Furane
GB2109373A (en) * 1981-10-28 1983-06-02 Ciba Geigy Ag Aminophenol acetic acid
EP0106800A1 (de) * 1982-10-08 1984-04-25 Ciba-Geigy Ag Furane
EP0107620A1 (de) * 1982-10-13 1984-05-02 Ciba-Geigy Ag Phenol-Derivate
EP0342665A2 (en) * 1988-05-20 1989-11-23 Takeda Chemical Industries, Ltd. Physiologically active substance tan-931, its derivatives, their production and use
WO1992020666A1 (en) * 1991-05-24 1992-11-26 Taiho Pharmaceutical Company, Limited Benzothiadiazine derivative
WO1995020652A1 (de) * 1994-01-28 1995-08-03 Medigene Gmbh Verfahren zur bestimmung der aktivität eines regulatorischen faktors sowie verwendung dieses verfahrens
DE4424712A1 (de) * 1994-07-13 1996-01-18 Basf Ag Verwendung von Benzaldehyden zum Markieren von Kohlenwasserstoffen
WO1997008133A1 (en) * 1995-08-22 1997-03-06 Japan Tobacco Inc. Amide compounds and use of the same
WO1997031891A1 (en) * 1996-03-01 1997-09-04 Merck & Co., Inc. Process for regioselective substitution of trifluorobenzoate or trifluorobenzonitrile
WO1998013502A2 (en) * 1996-09-27 1998-04-02 Icos Corporation Method to identify compounds for disrupting protein/protein interactions
GB2326410A (en) * 1997-06-18 1998-12-23 Merck & Co Inc Tocolytic Oxytocin Receptor Antagonists
WO1999014212A1 (en) * 1997-09-18 1999-03-25 Astrazeneca Ab Substituted chroman derivatives
WO1999029705A2 (en) * 1997-12-08 1999-06-17 Glycomed Incorporated Sialyl lewis x and sialyl lewis a glycomimetics
WO2000000644A1 (en) * 1998-06-30 2000-01-06 Sloan-Kettering Institute For Cancer Research Uses of dna-pk
WO2000017386A1 (en) * 1998-09-21 2000-03-30 Fox Chase Cancer Center Assays and novel cellular targets for therapeutic agents to treat retroviral infection
WO2000018750A2 (en) * 1998-09-28 2000-04-06 Kimberly-Clark Worldwide, Inc. Chelates comprising chinoid groups as photoinitiators

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5138245B2 (US07179912-20070220-C00074.png) * 1973-05-22 1976-10-20
US3904631A (en) * 1973-05-29 1975-09-09 Parke Davis & Co Novel thioxanthenone compounds and means of producing the same
US4003699A (en) * 1974-11-22 1977-01-18 Henkel & Cie G.M.B.H. Oxidation hair dyes based upon tetraaminopyrimidine developers
DE2737207A1 (de) * 1977-08-18 1979-03-01 Basf Ag Farbbildner fuer kopierverfahren
DE2807761A1 (de) * 1978-02-23 1979-08-30 Basf Ag Cumarinderivate
JPS5544830A (en) 1978-09-27 1980-03-29 Hodogaya Chem Co Ltd Pressure-sensitive copying paper
DE2950291A1 (de) 1979-12-14 1981-06-19 Basf Ag, 6700 Ludwigshafen Neue cumarinverbindungen und verfahren zur herstellung von cumarinverbindungen
JPS5788455A (en) * 1980-11-22 1982-06-02 Canon Inc Electrophotographic receptor
DE3141970A1 (de) 1981-10-22 1983-05-05 Vsesojuznyj naučno-issledovatel'skij institut lekarstvennych rastenij, Vilar, Moskovskaja oblast' Arzneimittel zur behandlung der durch den virus der herpes-gruppe erzeugten erkrankungen
US4539412A (en) * 1982-07-08 1985-09-03 Rensselaer Polytechnic Institute 7-Hydroxylucanthone, 7-hydroxhycanthone and their analogs
DE3800577A1 (de) * 1988-01-12 1989-07-20 Basf Ag 3-(4-amino-2-hydroxyphenyl)-1-oxo-isoindolenine, verfahren zu deren herstellung und deren verseifung zu 2-(4-amino-2-hydroxybenzoyl)-benzoesaeuren
WO1990014008A1 (en) 1989-05-25 1990-11-29 Sloan-Kettering Institute For Cancer Research Methods and compositions for inhibiting tumor cell growth
GB9018044D0 (en) 1990-08-16 1990-10-03 Ici Plc Tricyclic heterocyclic derivatives
WO1992016517A1 (en) 1991-03-22 1992-10-01 Xenova Limited Pharmaceutical xanthone derivatives
US5262549A (en) * 1991-05-30 1993-11-16 Polaroid Corporation Benzpyrylium dyes, and processes for their preparation and use
US5558043A (en) * 1994-10-06 1996-09-24 Givens; Donovan J. Lightweight, portable animal grooming stall
EP0793476B1 (fr) 1994-11-25 2001-10-10 Laboratoires De Biologie Vegetale Yves Rocher Utilisation de la mangiférine ou ses dérivés pour une application cosmétique
DE19501303A1 (de) 1995-01-18 1996-07-25 Henkel Kgaa Arylketone zum Färben keratinhaltiger Fasern
JPH11106371A (ja) * 1997-07-04 1999-04-20 Nisshin Flour Milling Co Ltd アシルヒドラゾン誘導体
JP4531149B2 (ja) 1997-10-17 2010-08-25 富山化学工業株式会社 含窒素三・四環式化合物およびそれを含有する抗ウイルス剤
US6555593B1 (en) * 1998-01-30 2003-04-29 Albemarle Corporation Photopolymerization compositions including maleimides and processes for using the same
AU756965B2 (en) * 1998-03-12 2003-01-30 Microbial Chemistry Research Foundation Benzofurylpyrone derivatives
US6407092B1 (en) * 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
US6297242B1 (en) * 1999-08-12 2001-10-02 Ortho-Mcneil Pharmaceutical, Inc. N-substituted amidine and guanidine oxazolidinone antibacterials and methods of use thereof
GB9920912D0 (en) 1999-09-03 1999-11-10 Indena Spa Novel derivatives of flavones,xanthones and coumarins
US6535593B1 (en) * 2000-02-28 2003-03-18 Simplified Development Corp. System and method for billing communications services provisioned on demand in converging telecommunications network
JP2001247459A (ja) * 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
EP1351946A2 (en) * 2000-09-01 2003-10-15 Icos Corporation Materials and methods to potentiate cancer treatment
JP3968978B2 (ja) 2000-09-20 2007-08-29 三菱化学株式会社 有機電界発光素子
AU2002352443A1 (en) 2001-12-21 2003-07-15 Consejo Superior De Investigaciones Cientificas Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1355173A (fr) * 1962-04-12 1964-03-13 Science Union & Cie Préparation de nouveaux dérivés de l'acide salicylique
FR8298M (US07179912-20070220-C00074.png) * 1967-07-20 1970-11-16
DE2922488A1 (de) * 1979-06-01 1980-12-11 Thiemann Chem Pharm Fab 2-hydroxy-4-methyl-benzolverbindungen, verfahren zu ihrer herstellung und ihre verwendung
EP0078241A2 (de) * 1981-10-28 1983-05-04 Ciba-Geigy Ag Furane
GB2109373A (en) * 1981-10-28 1983-06-02 Ciba Geigy Ag Aminophenol acetic acid
EP0106800A1 (de) * 1982-10-08 1984-04-25 Ciba-Geigy Ag Furane
EP0107620A1 (de) * 1982-10-13 1984-05-02 Ciba-Geigy Ag Phenol-Derivate
EP0342665A2 (en) * 1988-05-20 1989-11-23 Takeda Chemical Industries, Ltd. Physiologically active substance tan-931, its derivatives, their production and use
WO1992020666A1 (en) * 1991-05-24 1992-11-26 Taiho Pharmaceutical Company, Limited Benzothiadiazine derivative
WO1995020652A1 (de) * 1994-01-28 1995-08-03 Medigene Gmbh Verfahren zur bestimmung der aktivität eines regulatorischen faktors sowie verwendung dieses verfahrens
DE4424712A1 (de) * 1994-07-13 1996-01-18 Basf Ag Verwendung von Benzaldehyden zum Markieren von Kohlenwasserstoffen
WO1997008133A1 (en) * 1995-08-22 1997-03-06 Japan Tobacco Inc. Amide compounds and use of the same
WO1997031891A1 (en) * 1996-03-01 1997-09-04 Merck & Co., Inc. Process for regioselective substitution of trifluorobenzoate or trifluorobenzonitrile
WO1998013502A2 (en) * 1996-09-27 1998-04-02 Icos Corporation Method to identify compounds for disrupting protein/protein interactions
GB2326410A (en) * 1997-06-18 1998-12-23 Merck & Co Inc Tocolytic Oxytocin Receptor Antagonists
WO1999014212A1 (en) * 1997-09-18 1999-03-25 Astrazeneca Ab Substituted chroman derivatives
WO1999029705A2 (en) * 1997-12-08 1999-06-17 Glycomed Incorporated Sialyl lewis x and sialyl lewis a glycomimetics
WO2000000644A1 (en) * 1998-06-30 2000-01-06 Sloan-Kettering Institute For Cancer Research Uses of dna-pk
WO2000017386A1 (en) * 1998-09-21 2000-03-30 Fox Chase Cancer Center Assays and novel cellular targets for therapeutic agents to treat retroviral infection
WO2000018750A2 (en) * 1998-09-28 2000-04-06 Kimberly-Clark Worldwide, Inc. Chelates comprising chinoid groups as photoinitiators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. WINDHOLZ (ED.) ET AL: "The Merck Index, ninth edition" 1976 , MERCK & CO., INC. , RAHWAY, N.J., US XP002239312 page 84, no. 658; page 159, no. 1229; page 187, no. 1458; page 193, no. 1500; page 263, no. 2050; page 474, no. 3550; page 680, no. 5043; page 847, no. 6342; page 871, no. 6521; page 936, no. 7009; page 939, no. 7031; page 1069, no. 8011; page 1080, no. 8094; page 1275, no. 9592 *

Cited By (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179912B2 (en) 2000-09-01 2007-02-20 Icos Corporation Materials and methods to potentiate cancer treatment
US8242115B2 (en) 2000-09-01 2012-08-14 Luitpold Pharmaceuticals, Inc. Materials and methods to potentiate cancer treatment
US7674823B2 (en) 2001-08-14 2010-03-09 Cancer Research Technology Limited DNA-PK inhibitors
US7105518B2 (en) 2001-08-14 2006-09-12 Cancer Research Technology Limited Thiopyrane-4-ones as DNA protein kinase inhibitors
US7226918B2 (en) 2001-08-14 2007-06-05 Cancer Research Technology Limited DNA-PK inhibitors
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
JP2006523681A (ja) * 2003-03-24 2006-10-19 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド Ｄｎａ−ｐｋ阻害剤としてのキサントン、チオキサントンおよびアクリジノン
US8404681B2 (en) 2003-03-24 2013-03-26 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as DNA-PK inhibitors
WO2004085418A3 (en) * 2003-03-24 2005-01-27 Icos Corp Xanthones, thioxanthones and acridinones as dna-pk inhibitors
WO2004110418A2 (en) * 2003-06-10 2004-12-23 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
WO2004110418A3 (en) * 2003-06-10 2005-03-17 Kalypsys Inc Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
US7271195B2 (en) 2003-06-10 2007-09-18 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
US7429660B2 (en) 2003-08-13 2008-09-30 Kudos Pharmaceuticals Limited ATM inhibitors
JP2014148535A (ja) * 2004-03-15 2014-08-21 Sunesis Pharmaceuticals Inc Ｓｎｓ−５９５、及びその使用方法
JP2007529524A (ja) * 2004-03-15 2007-10-25 サネシス ファーマシューティカルズ， インコーポレイテッド Ｓｎｓ−５９５、及びその使用方法
EP1729770A1 (en) * 2004-03-15 2006-12-13 Sunesis Pharmaceuticals, Inc. Sns-595 and methods of using the same
US8822493B2 (en) 2004-03-15 2014-09-02 Sunesis Pharmaceuticals, Inc. SNS-595 and methods of using the same
US7968565B2 (en) 2004-03-15 2011-06-28 Sunesis Pharmaceuticals, Inc. Therapeutic combinations comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
EP1729770A4 (en) * 2004-03-15 2007-04-11 Sunesis Pharmaceuticals Inc SNS-595 AND METHODS OF USING THE SAME
JP2012140442A (ja) * 2004-03-15 2012-07-26 Sunesis Pharmaceuticals Inc Ｓｎｓ−５９５、及びその使用方法
JP2017095471A (ja) * 2004-03-15 2017-06-01 サネシス ファーマシューティカルズ， インコーポレイテッド Ｓｎｓ−５９５、及びその使用方法
US9980949B2 (en) 2004-03-15 2018-05-29 Sunesis Pharmaceuticals, Inc. SNS-595 and methods of using the same
AU2005222607B2 (en) * 2004-03-15 2010-11-25 Sunesis Pharmaceuticals, Inc. SNS-595 and methods of using the same
US7732483B2 (en) 2004-09-20 2010-06-08 Kudos Pharmaceuticals Limited DNA-PK inhibitors
US7402607B2 (en) 2004-09-20 2008-07-22 Kudos Pharmaceuticals Limited DNA-PK inhibitors
US7642254B2 (en) 2005-02-09 2010-01-05 Kudos Pharmaceuticals Limited ATM inhibitors
US7696203B2 (en) 2005-04-15 2010-04-13 Kudos Pharmaceuticals Limited DNA-PK inhibitors
WO2006117669A1 (en) * 2005-05-03 2006-11-09 Pfizer Inc. Amide resorcinol compounds
US7910582B2 (en) 2005-09-16 2011-03-22 Janssen Pharmaceutica Nv Cyclopropyl amines as modulators of the histamine H3 receptor
US8026242B2 (en) 2005-09-16 2011-09-27 Carruthers Nicholas I Cyclopropyl amines as modulators of the histamine H3 receptor
US7687499B2 (en) 2005-09-16 2010-03-30 Janssen Pharmaceutica Nv Cyclopropyl amines as modulators of the histamine H3 receptor
US8153793B2 (en) 2005-09-27 2012-04-10 Shionogi & Co., Ltd. Sulfonamide derivative having PGD2 receptor antagonistic activity
US8993763B2 (en) 2005-09-27 2015-03-31 Shionogi & Co., Ltd. Sulfonamide derivative having PGD2 receptor antagonistic activity
US9440938B2 (en) 2005-09-27 2016-09-13 Shionogi & Co., Ltd. Sulfonamide derivative having PGD2 receptor antagonistic activity
US7632838B2 (en) 2006-02-07 2009-12-15 Wyeth 11-beta HSD1 inhibitors
US7834178B2 (en) 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
US8580814B2 (en) 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US8124773B2 (en) 2006-06-12 2012-02-28 Sunesis Pharmaceuticals, Inc. 1,8-naphthyridine compounds for the treatment of cancer
US9676774B2 (en) 2006-06-12 2017-06-13 Sunesis Pharmaceuticals, Inc. Compounds and compositions for treatment of cancer
US8765954B2 (en) 2006-06-12 2014-07-01 Sunesis Pharmaceuticals, Inc. 1,8-naphthyridine compounds for the treatment of cancer
AU2006233256B2 (en) * 2006-10-30 2012-01-19 Armaron Bio Pty Ltd Improved flavonols
US8680273B2 (en) 2006-12-14 2014-03-25 Janssen Pharmaceutica Nv Process for the preparation of piperazinyl and diazepanyl benzamide derivatives
US7893257B2 (en) 2006-12-14 2011-02-22 Janssen Pharmaceutica Nv Process for the preparation of piperazinyl and diazepanyl benzamide derivatives
US8518872B2 (en) 2007-10-22 2013-08-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
US8269197B2 (en) 2009-07-22 2012-09-18 Intraop Medical Corporation Method and system for electron beam applications
US9650362B2 (en) 2009-09-11 2017-05-16 Probiodrug Ag Inhibitors
JP2013504544A (ja) * 2009-09-11 2013-02-07 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
US9173885B2 (en) 2009-09-11 2015-11-03 Probiodrug Ag Inhibitors
US9656098B2 (en) 2010-03-01 2017-05-23 Intraop Medical Corporation Radiotherapy combined with hypoxic cell sensitizers
WO2011109387A1 (en) * 2010-03-01 2011-09-09 Intraop Medical Corporation Radiotherapy combined with hypoxic cell sensitizers
US9393439B2 (en) 2010-03-01 2016-07-19 Intraop Medical Corporation Radiotherapy combined with hypoxic cell sensitizers
CN102803227A (zh) * 2010-03-16 2012-11-28 默克专利有限公司 吗啉基喹唑啉
WO2011113512A1 (de) * 2010-03-16 2011-09-22 Merck Patent Gmbh Morpholinylchinazoline
JP2013522249A (ja) * 2010-03-16 2013-06-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング モルホリニルキナゾリン
US9126952B2 (en) 2010-03-16 2015-09-08 Merck Patent Gmbh Morpholinylquinazolines
WO2011123890A1 (en) 2010-04-06 2011-10-13 Peter Maccallum Cancer Institute Radioprotector compounds and methods
US9133178B2 (en) 2010-10-27 2015-09-15 Proximagen Limited Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer'S disease
US11129828B2 (en) 2011-08-22 2021-09-28 Takeda Pharmaceutical Company Limited Pyridazinone compounds and their use as DAAO inhibitors
AU2012339196B2 (en) * 2011-11-18 2017-04-27 Merck Patent Gmbh Morpholinyl benzotriazine for use in cancer therapy
CN103930408A (zh) * 2011-11-18 2014-07-16 默克专利股份公司 用于癌症治疗的吗啉基苯并三嗪
WO2013072015A1 (de) * 2011-11-18 2013-05-23 Merck Patent Gmbh Morpholinylbenzotriazine zur anwendung in der krebstherapie
US9187469B2 (en) 2011-11-18 2015-11-17 Merck Patent Gmbh Morpholinylbenzotriazines for use in cancer therapy
US11008305B2 (en) 2012-04-24 2021-05-18 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US10442791B2 (en) 2012-04-24 2019-10-15 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US10391095B2 (en) 2012-04-24 2019-08-27 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
CN104640852B (zh) * 2012-04-24 2017-04-26 沃泰克斯药物股份有限公司 Dna‑pk抑制剂
US10501439B2 (en) 2012-04-24 2019-12-10 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
CN104640852A (zh) * 2012-04-24 2015-05-20 沃泰克斯药物股份有限公司 Dna-pk抑制剂
US10076521B2 (en) 2012-04-24 2018-09-18 Vertex Pharamceuticals Incorporated DNA-PK inhibitors
US9878993B2 (en) 2012-04-24 2018-01-30 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors for treatment of cancer
US11021465B2 (en) 2012-04-24 2021-06-01 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9925188B2 (en) 2012-04-24 2018-03-27 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors and uses thereof
KR102216284B1 (ko) 2013-03-12 2021-02-18 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제
KR20150126051A (ko) * 2013-03-12 2015-11-10 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제
CN105246883A (zh) * 2013-03-12 2016-01-13 沃泰克斯药物股份有限公司 Dna-pk抑制剂
EP3985003A1 (en) * 2013-03-12 2022-04-20 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
CN107200749A (zh) * 2013-03-12 2017-09-26 沃泰克斯药物股份有限公司 Dna‑pk抑制剂
WO2014159690A1 (en) * 2013-03-12 2014-10-02 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
AU2018236800B2 (en) * 2013-03-12 2020-04-09 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
AU2014244555B2 (en) * 2013-03-12 2018-06-28 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
JP2016516706A (ja) * 2013-03-12 2016-06-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤
CN107200749B (zh) * 2013-03-12 2019-09-03 沃泰克斯药物股份有限公司 Dna-pk抑制剂
EP3527563A1 (en) * 2013-03-12 2019-08-21 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
RU2676259C2 (ru) * 2013-03-12 2018-12-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы днк-пк
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
EA024384B1 (ru) * 2013-06-27 2016-09-30 Институт Нефтехимических Процессов Им. Академика Ю. Мамедалиева, Нан Азербайджана Применение комплексной соли 2-морфолилметил-5-метилфенола в качестве пестицида против оидиума в плодах и листьях винограда
JP2016533366A (ja) * 2013-10-17 2016-10-27 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤
WO2015058031A1 (en) * 2013-10-17 2015-04-23 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
US10039761B2 (en) 2013-10-17 2018-08-07 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
CN105636958B (zh) * 2013-10-17 2018-01-05 沃泰克斯药物股份有限公司 Dna‑pk抑制剂
US10716789B2 (en) 2013-10-17 2020-07-21 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
CN105636958A (zh) * 2013-10-17 2016-06-01 沃泰克斯药物股份有限公司 Dna-pk抑制剂
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
US11413255B2 (en) * 2015-06-29 2022-08-16 Montefiore Medical Center Multifunctional cytoprotectant for treatment of pathogenic processes mediated by oxidative stress and toxic electrophiles
US10604535B2 (en) 2016-02-05 2020-03-31 Denali Therapeutics Inc. Compounds, compositions and methods
US9896458B2 (en) 2016-02-05 2018-02-20 Denali Therapeutics Inc. Compounds, compositions and methods
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
US10131676B2 (en) 2016-02-05 2018-11-20 Denali Therapeutics Inc. Compounds, compositions and methods
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
RU2758669C2 (ru) * 2016-09-27 2021-11-01 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
US11072618B2 (en) 2016-12-09 2021-07-27 Denali Therapeutics Inc. Compounds, compositions and methods
US11603523B2 (en) 2019-01-18 2023-03-14 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
CN111978139A (zh) * 2020-09-04 2020-11-24 许昌学院 一种水相中光催化一锅法合成苯酚或其衍生物的方法
CN111978139B (zh) * 2020-09-04 2023-04-07 许昌学院 一种水相中光催化一锅法合成苯酚或其衍生物的方法
US11980633B2 (en) 2021-07-29 2024-05-14 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
CN114933528A (zh) * 2022-05-30 2022-08-23 湖南大学 一种制备芳酰氧基烷基碘化物及其转化应用方法的新方法
CN114933528B (zh) * 2022-05-30 2024-03-29 湖南大学 一种制备芳酰氧基烷基碘化物及其转化应用方法的新方法

Also Published As

Publication number Publication date
US20020165218A1 (en) 2002-11-07
WO2002020500A3 (en) 2003-07-31
US7179912B2 (en) 2007-02-20
AU2001288432A1 (en) 2002-03-22
US20080090782A1 (en) 2008-04-17
EP1351946A2 (en) 2003-10-15
US8242115B2 (en) 2012-08-14

Similar Documents

Publication Publication Date Title
US8242115B2 (en) Materials and methods to potentiate cancer treatment
US8404681B2 (en) Xanthones, thioxanthones and acridinones as DNA-PK inhibitors
US7057046B2 (en) Lactam glycogen phosphorylase inhibitors and method of use
US6130217A (en) Compounds enhancing antitumor activity of other cytotoxic agents
JP5745661B2 (ja) ７−置換インドールＭｃｌ−１阻害薬
AU2009322219B2 (en) Sulfonamide derivatives as Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CA2744708C (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP5689119B2 (ja) ジヒドロピリミジン化合物及び合成方法、医薬組成物及びその使用
WO1994022846A1 (en) Compounds enhancing antitumor activity of other cytotoxic agents
US7098235B2 (en) Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US7365061B2 (en) 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
RU2138482C1 (ru) Производные аминостильбазола или их гидраты, или их соли и фармацевтическая композиция на их основе
EA015253B1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
Madbouly et al. Design and synthesis of novel quinazolinone–chalcone hybrids as potential apoptotic candidates targeting caspase-3 and PARP-1: in vitro, molecular docking, and SAR studies
US20210380558A1 (en) Beta-catenin and b-cell lymphoma 9 (bcl9) inhibitors
US7226942B2 (en) 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US11345692B1 (en) 3-vinylquinolines as cancer cells inhibitors
RU2663623C2 (ru) Фталазиновые производные
US20060111415A1 (en) 2-Aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
AU2015221495B2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US10385040B2 (en) Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same
KR20240057820A (ko) 신규 피라졸로-옥소티아졸리딘 유도체 및 이를 포함하는 알칼리성 포스파타제 억제제

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001968164

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001968164

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP